3224.TWO MetaTech AP
- Market cap
- TWD 2.25B
- P/E
- -
- P/B
- 1.71x
- ROE
- -0.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 3224.TWO undervalued?
Graham numberThe Graham number of MetaTech AP cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MetaTech AP fundamental analysis
No fundamental analysis for MetaTech AP yet.
MetaTech AP stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MetaTech AP
MetaTech (AP) Inc., together with its subsidiaries, engages in the wholesale and retail of electronic products and equipment in Hongkong, Taiwan, Singapore, and China. The company engages in the cell sheet development and medical production; cell therapy; and travel business. It also develops and operates biomedicine-related business. The company was incorporated in 1998 and is headquartered in New Taipei City, Taiwan.
Full company profileMetaTech AP financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MetaTech AP annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.43B | 1.46B | 1.41B | 1.58B | 2.01B | 1.85B | 1.45B | 1.41B | 1.51B | 1.65B |
| Gross Profit | 162M | 150M | 142M | 171M | 265M | 215M | 167M | 173M | 197M | 246M |
| Operating Income | 11.4M | -82.7M | -116M | -86.3M | -33.7M | -45.1M | -200M | -224M | -231M | -164M |
| EBITDA | 15.0M | -58.5M | -80.1M | -49.1M | 12.8M | 1.18M | -149M | -95.4M | -167M | -56.2M |
| Net Income | 5.19M | -57.7M | -92.7M | -82.5M | -24.1M | -11.8M | -132M | -68.8M | -104M | -12.4M |
| EPS | 0.12 | -0.98 | -1.58 | -1.42 | -0.40 | -0.17 | -1.94 | -1.01 | -1.53 | -0.16 |
| Balance Sheet | ||||||||||
| Total Assets | 780M | 1.31B | 1.51B | 1.50B | 3.54B | 3.49B | 3.29B | 3.27B | 3.27B | 3.81B |
| Total Liabilities | 180M | 238M | 501M | 581M | 581M | 553M | 552M | 664M | 921M | 1.16B |
| Shareholders' Equity | 600M | 1.07B | 1.00B | 915M | 1.29B | 1.31B | 1.18B | 1.14B | 1.03B | 1.39B |
| Cash & Short-term Investments | 203M | 494M | 364M | 381M | 2.16B | 2.16B | 2.24B | 1.62B | 1.22B | 1.39B |
| Total Debt | - | - | - | 388M | 309M | 304M | 404M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -68.8M | 5.98M | -60.1M | -21.4M | -212M | 1.68M | 99.4M | -180M | -205M | -92.1M |
| Capital Expenditure | 29.7M | 94.1M | 34.2M | 28.6M | 5.95M | 20.6M | 86.9M | 444M | 428M | 599M |
| Free Cash Flow | -112M | -211M | -213M | -50.1M | -218M | -18.9M | 12.5M | -624M | -632M | -691M |
| Ratios | ||||||||||
| ROE | 0.9% | -5.4% | -9.2% | -9.0% | -1.9% | -0.9% | -11.2% | -6.0% | -10.1% | -0.9% |
| ROA | 0.7% | -4.4% | -6.2% | -5.5% | -0.7% | -0.3% | -4.0% | -2.1% | -3.2% | -0.3% |
| Net Profit Margin | 0.4% | -4.0% | -6.6% | -5.2% | -1.2% | -0.6% | -9.1% | -4.9% | -6.9% | -0.7% |
| Debt to Equity | - | - | - | 0.42x | 0.24x | 0.23x | 0.34x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MetaTech AP dividends
MetaTech AP has not paid dividends in the last 9 fiscal years.
Last stock split: 0.714218:1 on Dec 23, 2013.
Who owns MetaTech AP
- Insiders 51.10%
- Institutions 4.17%
- Public & others 44.73%
- Shares outstanding 78.1M
- Free float 42.8M
MetaTech AP company profile
- Company name
- MetaTech AP
- Ticker
- 3224.TWO
- ISIN
- TW0003224002
- Exchange
- Taiwan OTC Exchange
- Sector
- Technology
- Industry
- Electronic Equipment, Instruments & Components
- Fiscal year end
- December
- Address
- No. 75, Xintai 5th Road, New Taipei City, Taiwan, 22101
- Phone
- 886 2 2698 3466
- Website
- metatech.com.tw
About MetaTech AP
MetaTech (AP) Inc., together with its subsidiaries, engages in the wholesale and retail of electronic products and equipment in Hongkong, Taiwan, Singapore, and China. The company engages in the cell sheet development and medical production; cell therapy; and travel business. It also develops and operates biomedicine-related business. The company was incorporated in 1998 and is headquartered in New Taipei City, Taiwan.
MetaTech AP management
5- Mr. Tsung-Chi ChenChairman of the Board · born 1964
- Mr. Hung-Te TangGM & Assistant Manager of Investment Relationship Department · born 1965
- Meng Fan ShenDirector of Finance Department & Accounting Supervisor
- Hui Jing ZhouDeputy Director of General Administration Office
- Yingzhen YangChief Executive Officer of Biomedical Business Group